Form D · Biotechnology

Vantix Diagnostics, Inc.

Pelham, NH · CIK 0001558003

Offering snapshot reported Feb 11, 2014 · SEC filing

Reported sold
$4.95M
Offering amount: $16M
Investors reported
52
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 13, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported investors0 → 52

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 11, 2014Amendment$4,947,000No comparison52SEC filing
Jan 23, 2013InitialYet to sellNo comparison0SEC filing
Jan 23, 2013InitialYet to sellNo comparison0SEC filing
Oct 19, 2012Amendment$1,140,000$890,000vs Sep 12, 201213SEC filing
Sep 12, 2012Initial$250,000No comparison5SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$720K (estimated)
Finders' fees
$0
Form D file number
021-190613
The offering amount is $16,000,000 which may be oversubscribed with sales of an additional $1,600,000 in securities.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANoneDawson James Securities Inc. · CRD 130645

Source: Form D, filed Feb 11, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Douglas Armstrong Director
Doug Armstrong Director
Steve Lufkin Director, Executive, Promoter
Anthony Pintsopoulos Promoter
Richard Rappaport Promoter
Richard Wardle Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
70 Bridge St. #8
Pelham, NH, 03076-3470